Navigation Links
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)

WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of Neurochem Inc.'s North American Phase III clinical trial for tramiprosate (ALZHEMED(TM)) will present today an update on Neurochem's investigational product candidate for the treatment of Alzheimer's disease (AD). The presentation by Dr. Aisen will take place at the Intervention and Treatment Session, scheduled from 2:30 - 4:30 P.M. (ET), at the Alzheimer's Association International Conference on Prevention of Dementia in Washington, DC. In his presentation entitled, A Phase III Study of the Efficacy, Safety and Disease Modification Effect of Tramiprosate in Mild-to-Moderate Alzheimer's Disease, Dr. Aisen will review the Phase III clinical trial and provide an update.

Neurochem announced in April 2007 that an adjustment to the initial statistical model, as set out in the statistical plan, would be necessary to provide accurate results. The procedure to arrive at a reliable model involves a detailed analysis of potential confounding factors, and Dr. Aisen will present on the progress to date. In addition, Dr. Aisen will provide an update on the progress in the analysis of the Phase III clinical trial primary endpoint data. Some preliminary descriptive data shows numerical differences in favor of tramiprosate (ALZHEMED(TM)) on the primary clinical endpoint and also shows differences between groups on the primary disease modification endpoint as measured by magnetic resonance imaging (MRI). However, work regarding the adjustment of the statistical model is ongoing and, therefore results of the Phase III clinical trial cannot be derived from the preliminary data nor can statistical significance be assigned at this time. Accordingly, no predictions or conclusions can yet be made regarding the outcome of the Phase III study.






Page: 1 2 3 4

Related medicine technology :

1. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
2. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
6. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
7. Clinical Update - Debio 9902 (ZT-1) for Alzheimers Disease
8. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
9. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
10. Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimers Disease
11. Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimers Drug
Post Your Comments:
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Oct. 21 The U.S. Food and Drug ... been added to the label for the HIV ... effects on the heart when used with Norvir ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ...
... 21 Span-America Medical Systems, Inc. (Nasdaq:  SPAN) will ... conference call on Tuesday, November 2, 2010, covering results ... be released after the regular close of trading the ... conference call will be available online at  www.spanamerica.com ...
Cached Medicine Technology:New Label Changes for Commonly Prescribed HIV Drug Invirase 2
(Date:1/23/2015)... 23, 2015 Hastings and Hastings, a law ... a record number of legal representation client review requests for ... been a steady rise in the number of slip and ... home throughout the Valley. With that said, a large number ... by an experienced law firm. Hastings and Hastings is a ...
(Date:1/22/2015)... its top dressmaking technologies, has been a leading dress supplier ... latest designs of wedding dresses and launching a site-wide promotion ... the fresh new products are designed for 2015, and they ... All the clothes from LunaDress follow up with the latest ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... January 22, 2015 A new white ... experience and person-centeredness in the long-term care environment as ... across the continuum. The paper, “The Power of Person-Centeredness ... perspectives and practices of the patient, resident and family ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... emergence of minimally invasive surgery procedures in operating theatres. ... leaves much to be desired. Researcher Magdalena Chmarra has ... training system which records and analyses the surgeon,s movements. ... time, an objective benchmark for measuring a surgeon,s basic ...
... ICU, and All-Private Hospital WingNEW ORLEANS, Jan. 12 At ... on Monday, January 12, 2009 , DHH Secretary Alan ... Ochsner Baptist Medical Center and the community to celebrate the ... room hospital wing at 2700 Napoleon Avenue in ...
... NEW YORK and SAN FRANCISCO, Jan. 12 ... the largest independent communications agency focused exclusively on ... focused on helping companies build health-based brands, today ... services agency that works with healthcare and technology ...
... AMERIGROUP Corporation (NYSE: AGP ) announced ... Institute, which will enhance the Company,s focus on improving ... are financially vulnerable, who have disabilities or who are ... a joint venture of AMERIGROUP Corporation and the AMERIGROUP ...
... /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... medical devices worldwide, today announced selected preliminary,unaudited results ... The,preliminary results reported below include the results ... Datascope ("DPM") starting from May,1, 2008. , ...
... Bioequivalence Study to Evaluate the Safety, Tolerability, and ... Laboratories, Inc, an emerging specialty pharmaceutical company dedicated ... in opioid pharmaceuticals, announced today the initiation of ... CL-108. "After many months, development in the ...
Cached Medicine News:Health News:New training method helps surgeons evaluate their own minimally invasive surgery skills 2Health News:Ochsner Baptist Opens ER and Clara Wing 2Health News:Ochsner Baptist Opens ER and Clara Wing 3Health News:Ochsner Baptist Opens ER and Clara Wing 4Health News:WeissComm Group Acquires Strategic Branding Firm ODA and Enters Alliance With Patient-Focused Health Advocacy Strategies to Diversify Business and Expand Offerings 2Health News:WeissComm Group Acquires Strategic Branding Firm ODA and Enters Alliance With Patient-Focused Health Advocacy Strategies to Diversify Business and Expand Offerings 3Health News:AMERIGROUP to Establish Public Policy Institute 2Health News:AMERIGROUP to Establish Public Policy Institute 3Health News:Mindray Announces Preliminary 2008 Operating Results 2Health News:Mindray Announces Preliminary 2008 Operating Results 3Health News:Mindray Announces Preliminary 2008 Operating Results 4Health News:Charleston Laboratories, Inc. Phase I Clinical Trial 2
... images are transmitted through sorted ... picture and transmit it to ... flexoscopes are designed for rough, ... repaired at low cost if ...
The flexible endoscope was mainly developed for the pure neuroendoscopy. Due to the working channel it is ideal suitable for therapeutic indications e.g. subdural hematomas, cysts or intraventricular...
The original Zeppelin High-Speed Motordrill System has been developed to rapidly cut bone, plastic and metal with utmost precision. 120-150 psi - 90.000 rpm - 90g - autoclavable at <134 C....
The Hilan pneumatic high speed drill system consists of a pneumatic motor and drill with various cutting attachments....
Medicine Products: